TicSalut
Generalitat de Catalunya - Departament de Salut
Home > Innovation > internacional > TicSalut in European Projects

TicSalut in European Projects

← Back to projects

m -RESIST: Mobile Therapeutic Attention for Pacients with Treatment Resistant Ezquizofrenia

m-RESIST Project (Mobile Therapeutic Attention for Patients with Treatment Resistant Schizophrenia) is a European Project aimed to develop a therapeutic program that draws on the support of mobile devices to actively involve patients with treatment-resistant schizophrenia, to make them capable of self-managing their own illness, as well as to support their carers. m-RESIST will bring forth a new technical focus for health treatments, which will allow the behaviour patterns found in many patient data to be analysed in order to identify the risks and shortcomings of the treatments.

The m-RESIST solution will be tested in 3 pilot trials with real users in Catalonia, Israel and Hungary.

m-RESIST Project (Mobile Therapeutic Attention for Patients with Treatment Resistant Schizophrenia), a European Project aimed to develop a therapeutic program that draws on the support of mobile devices to actively involve patients with treatment-resistant schizophrenia, to make them capable of self-managing their own illness, as well as to support their carers.

A model of analysis will be implemented, in order to move forward in understanding resistant schizophrenia. Besides, project activities will help to predict patient’s behaviour and to allow the establishment of a reaction alert system, as well as to draw up protocols and recommendations to give doctors support in the clinical decisions. By linking data mining tools with a high-level predictive model, m-RESIST will bring forth a new technical focus for health treatments, which will allow the behaviour patterns found in many patient data to be analysed in order to identify the risks and shortcomings of the treatments.

Start date: 01/01/2015 - End date: 31/12/2017

BudgetFundingCoordinator
4M€H2020 PHC-26-2014Fundació TicSalut

Innovation

It is a highly innovative project, as it is the first time in Spain and Europe that a therapeutic project is developed for schizophrenic patients resistant to treatment using mHealth tools. These tools will be developed to allow patients to play a more active role in managing their own illness, and we hope this will have a positive effect on adherence to treatment and a reduction of persistent serious symptoms, relapses and hospitalisation”, says Dr. Iluminada Corripio, the leader of the m-RESIST project at the Hospital de la Santa Creu i Sant Pau.

Benefits

We hope that m-Resist will bring a real benefit for schizophrenic patients by extending the area of application of the personalised pharmacological and psychological treatment, not only improving the persistence of care and the participation of the carers, but also by creating a broad database to allow development in characterising the profile of the resistant schizophrenic”, says Dr. Asaf Caspi, Director of Ambulatory Psychiatric Services at the Sheba Medical Center (Israel), who leads m-RESIST project at Gertner Institute.

Entities

  1. Fundació TicSalut (Spain)
  2. Hospital de la Santa Creu i Sant Pau (Spain)
  3. Parc Sanitari Sant Joan de Déu (Spain)
  4. The Gertner Institute for Epidemiology & Health Policy Research (Israel)
  5. Oulun Yliopisto (Finland)
  6. iMinds VZW (Belgium)
  7. IBM Global Services España SA (Spain)
  8. Athens Technology Center SA (Greece)
  9. Semmelweis Egyetem (Hungary)
  10. Agència De Qualitat I Avaluació Sanitàries De Catalunya (Spain)
  11. AB.ACUS SRL (Italy)
  12. Institute of Communication and Computer Systems (Greece)